Sage Acquisition - Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands	Jul. 31, 2025	Sep. 30, 2025	Dec. 31, 2024
Business Combination [Line Items]
Goodwill		$ 119,080	$ 117,019
Fair value of contingent consideration		$ 11,448	$ 47,340
Sage Therapeutics, Inc.
Business Combination [Line Items]
Cash and cash equivalents	$ 243,197
Marketable securities	93,181
Accounts receivable, net	23,291
Inventories, net	50,714
Prepaid expenses and other current assets	18,674
Restricted cash	1,450
Operating lease asset	5,630
Intangible assets	166,500
Other assets	1,102
Total fair value of assets acquired	603,739
Accounts payable and accrued liabilities	44,232
Operating lease liability	12,380
Total fair value of liabilities assumed	56,612
Total identifiable net assets	547,127
Goodwill	2,061
Total purchase price	549,188
Cash consideration paid for Sage's common stock	561,000
Cash consideration paid for cash settlement of Sage's equity awards	4,073
Fair value of contingent consideration	11,448
Sage Therapeutics, Inc. | Common Stock
Business Combination [Line Items]
Cash consideration paid for Sage's common stock	$ 533,667